F. Wiesbauer(1)*, G. Heinze(2)*, C. Mitterbauer(3), F. Harnoncourt(4), WH. Hörl(3), R. Oberbauer(3,4,5)
1- Department of Cardiology, Medical University of Vienna, Austria
2- Core Unit of Medical Statistics and Informatics, Medical University of Vienna, Austria
3- Department of Nephrology, Medical University of Vienna, Austria
4- Department of Nephrology, KH Elisabethinen, Linz, Austria
5- Austrian Dialysis and Transplant Registry, Wels, Austria
* Both authors contributed equally to the paper
![Webtable 1: Webtable 1:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-1.jpg)
Characteristics of all 1,829 patients with graft survival of at least 90 days
View PDF![Webfigure 1: Webfigure 1:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webfigure-1.jpg)
Hazard function (risk for graft loss or death per year)
View PDF![Webtable 2: Webtable 2:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-2.jpg)
Complete Case Only analysis
View PDF![Webfigure 2: Webfigure 2:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webfigure-2.jpg)
Cardiovascular death outcome
Among the 2041 patients, 223 died with confirmed cardiovascular causes. 35 of these 223 deaths occurred before day 90. Extended Kaplan-Meier plot stratified for (timedependent) statin
![Webtable 3: Webtable 3:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-3.jpg)
Analysis of sensitivity of multiple imputation approach (comparison of results from multiple imputation after randomly deleting data and non-randomly deleting data)
View PDF![Webfigure 3a: Webfigure 3a:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webfigure-3a.jpg)
![Webfigure 3b: Webfigure 3b:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webfigure-3b.jpg)
Analysis including events between days 0 and 90
Kaplan-Meier analysis
b actual graft survival
View PDF![Webfigure 3c: Webfigure 3c:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webfigure-3c.jpg)
Analysis including events between days 0 and 90
Kaplan-Meier analysis
c functional graft survival
View PDF![Webtable 4a: Webtable 4a:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-4a.jpg)
![Webtable 4b: Webtable 4b:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-4b.jpg)
![Webtable 4c: Webtable 4c:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-4c.jpg)
![Webtable 5: Webtable 5:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-5.jpg)
MSM analysis without statin users at baseline
View PDF![Webtable 6: Webtable 6:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-6.jpg)
Clinical expertise models (HLA mismatches, CIT, Induction therapy, donor age forced into model)
View PDF![Webtable 7a: Webtable 7a:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-7a.jpg)
Interaction analysis (HR of statin use in subgroups which were close to significant)
a Patient survival
View PDF![Webtable 7b: Webtable 7b:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-7b.jpg)
Interaction analysis (HR of statin use in subgroups which were close to significant)
b actual graft survival
View PDF![Webtable 7c: Webtable 7c:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-7c.jpg)
Interaction analysis (HR of statin use in subgroups which were close to significant)
c functional graft survival
View PDF![Webtable 8a: Webtable 8a:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-8a.jpg)
![Webfigure 8a: Webfigure 8a:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webfigure-8a.jpg)
![Webtable 8b: Webtable 8b:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-8b.jpg)
![Webfigure 8b: Webfigure 8b:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webfigure-8b.jpg)
![Webtable 8c: Webtable 8c:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-8c.jpg)
![Webfigure 8c: Webfigure 8c:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webfigure-8c.jpg)
![Webtable 9: Webtable 9:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-9.jpg)
Analysis of time to (biopsy confirmed) acute rejection
Results from Kaplan-Meier analysis and Cox regression. Dependent variable: BCAR up to one year after transplantation.
![Webtable 10: Webtable 10:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-10.jpg)
Multivariable Cox’s proportional hazards model assessing the confounder-adjusted association of statin treatment on actual graft survival (graft failure and death with functioning graft counted as endpoints)
View PDF![Webfigure 10: Webfigure 10:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webfigure-10.jpg)
Kaplan-Meier curves of actual graft survival
View PDF![Webtable 11: Webtable 11:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webtable-11.jpg)
Multivariable Cox analysis assessing the effect of statin treatment on patient survival and functional graft survival.
View PDF![Webfigure 11: Webfigure 11:](https://www.meduniwien.ac.at/nephrogene/wp-content/uploads/2013/03/73_Webfigure-11.jpg)
Onset of statin treatment after transplantation.
View PDF